Original Research

Hepatocellular Carcinoma (HCC) in HCV-Related Liver Cirrhosis After Sustained Viral Response (SVR)

Syed Hasnain Abbas1
Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat, Sindh
Azhar Hussain1
Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat, Sindh
Hafiz Fahad Ullah Saeed2
King Edward Medical University, Mayo Hospital, Lahore
Muhammad Usman2
King Edward Medical University, Mayo Hospital, Lahore
Madho Mal3
Liaquat University of Medical & Health Sciences, Jamshoro
Usman Ismail2
King Edward Medical University, Mayo Hospital, Lahore
Muhammad Umair2
King Edward Medical University, Mayo Hospital, Lahore
Muhammad Furqan2
King Edward Medical University, Mayo Hospital, Lahore
Talal Khurshid Bhatti4
SZABMU & PIMS, Islamabad
Ejaz Shah5
HSHS Saint John Hospital Internal Medicine, Springfield, USA

✉ Correspondence: Syed Hasnain Abbas Email: azharhussain0139@gmail.com

DOI https://doi.org/10.70302/jpsim.v4i1.2307
Volume: 4, Issue 1 Pages: 29–34 Published: 13 Feb 2023
Received: 07 Nov 2022 Accepted: 15 Dec 2022 Published Online: 13 Feb 2023

Abstract

Objective

Effectiveness of the direct-acting antivirals (DAAs) regarding the achievement of SVR post-treatment and its impact on the future occurrence of hepatocellular carcinoma (HCC) post-treatment of DAAs in Hepatitis C-related liver cirrhosis.

Methodology

It was a cohort study that was done on 359 Hepatitis C patients who were given Ribavarin-Sofosfubuvir & Daclatasvir. We experienced 41.1% (158) lost follow-up. Only 86/201 (43.2%) completed follow-up. The study population was divided into two groups (SVR achieved vs didn’t SVR achieve). Each group was further subdivided into two groups: developed HCC or did not develop HCC post-treatment of DAAs.

Results

86 subjects who had median age of 50.6 ± 10.65 years who completed triple therapy regime and follow-up, were analyzed. The average follow-up period was 45 weeks (24-68 weeks). Out of 86 patients, 81 (94%) achieved SVR12 with triple therapy of Sofosbuvir-Daclasavir plus Ribavirin. Only 2(2.4%) patients out of 81 developed HCC after the achievement of SVR, while 3/5 (60%) of patients developed HCC who did not achieve SVR. The rate of achievement of SVR was quite lower in the group diagnosed with HCC than those who did not develop HCC post-treatment of DAAs (66.6% v 96.8%, p=0.023). HCC occurrence duration was 31-48 weeks after SVR achievement post-treatment of DAAs.

Conclusions

SVR achieved by Sofosbuvir-Daclasavir plus Ribavirin plus ribavirin decreases the occurrence of HCC but doesn’t eliminate the chances of developing HCC (66.3 %- or 3.3 times lesser risk).

Keywords
Liver cirrhosis sustained viral response hepatocellular carcinoma (HCC)

How to Cite This Article

Abbas SH, Hussain A, Saeed HFU, Usman M, Mal M, Ismail U, et al.. Hepatocellular Carcinoma (HCC) in HCV-Related Liver Cirrhosis After Sustained Viral Response (SVR). J Pak Soc Intern Med. 2023;4(1):29–34. doi:10.70302/jpsim.v4i1.2307

⭳ Download XML (JATS) ⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

Data Availability

Data are available from the corresponding author on reasonable request.

References

  1. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420.
  2. World Health Organization. 15 million people affected with hepatitis B and C in Pakistan: Government announces ambitious plan to eliminate hepatitis. Available from: [https://www.who.int/hepatitis/news-events/pakistan-hepatitis-elimination-plan/en/]
  3. Ahmed OA, Safwat E, Khalifa MO, Elshafie AI, Fouad MH, Salama MM, et al. Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village. Int J Hepatol. 2018;https://doi.org/10.1155/2018/9616234. doi:10.1155/2018/9616234
  4. Scognamiglio P, Galati V, Navarra A, Longo MA, Aloisi MS, Antonini MG. Impact of hepatitis C virus infection on lifestyle. World J Gastroenterol. 2007; 13(19): 2722-6.
  5. El Kassas M, Alboraie M, Naguib M. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019; 30(8): 708-13.
  6. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Digest Liver Dis. 2014;46(Sup-1):S186-96.
  7. Hézode C, Fourati S, Chevaliez S, Scoazec G, Soulier A, Varaut A, et al. Sofosbuvir-daclatasvir-simeprevir plus ribavirin in direct-acting antiviral–experienced patients with hepatitis C. Clin Infect Dis. 2017;64(11):1615-8.
  8. Ahmadi R. Efficiency of Neuropsychological Methods in Enhancing the Comprehension of Students Suffered from Developmental Dyslexia. Int J Scientific Eng Res. 2015;6(10):601-8.
  9. Bansal S et al. Impact of all oral anti-hepatitis C virus therapy; World J Hepatol 2015 April 18; 7(5): 806-13
  10. Nobili, V., Carter-Kent, C. & Feldstein, A.E. The role of lifestyle changes in the management of chronic liver disease. BMC Med.2011;https://doi.org/10.1186/1741-7015-9-70 doi:10.1186/1741-7015-9-70
  11. Constant A, Castera L, Dantzer R, Couzigou P, De Ledinghen V, Demotes-Mainard J, Henry C. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: Evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiat. 2005.66(8), 1050-7.
  12. Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111(6):808-16.
  13. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12(8):1349-59.
  14. Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Brit Med Bul. 2015;113(1):31-44
  15. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterol. 2017;153(4):996-1005.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. Authors retain copyright. © 2023 The Author(s).